Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00691769

Enrollment

Registered

2008-06-05

Start date

2006-04-26

Completion date

2012-11-26

Last updated

2018-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Centrifugal Scarring Alopecia, Discoid Lupus Erythematosus, Lichen Planopilaris

Keywords

alopecia, lupus

Brief summary

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

Detailed description

This is a single-center study, designed to evaluate the expression of Fas protein in skin biopsies of patients with scarring alopecia including fourteen patients with central centrifugal scarring alopecia (CCSA), three patients with lichen planopilaris (LP) and three patients with discoid lupus erythematosus (DLE). Skin biopsies of five healthy participants will be used as controls.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Participants ages 30 years or older with a biopsy- proven diagnosis of CCSA. * Undergone standard of care treatment for CCSA by a WFUSM Dermatologist * Women of child bearing age will be required to have a negative pregnancy test in order to participate in the study * Participants ages 30 years or older with a biopsy- proven diagnosis of LP. * Participants ages 30 years or older with a biopsy- proven diagnosis of DLE. * Healthy participants must be ages 30 years or older.

Exclusion criteria

* Age less than 30 years of age. * Clinically evident bacterial or viral infection of the scalp. * Pregnant or nursing woman of child-bearing potential. * Participation in any other investigative research study involving study medication. * Inability to return for the biopsy visit.

Design outcomes

Primary

Measure	Time frame
To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA), lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls.	8 weeks

Secondary

Measure	Time frame
To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids.	8 weeks

Countries

United States

Outcome results